title: Ultrasound biomicroscopy study of vitreous incarceration subsequent to intravitreal injections.
abstract: OBJECTIVE
  To study the existence of vitreous incarceration by ultrasound biomicroscopy (UBM) at the pars plana after direct intravitreal injection of triamcinolone acetonide ± bevacizumab without anterior chamber paracentesis.
  
  
  METHODS
  Interventional case series.
  
  
  METHODS
  Patients undergoing intravitreal injection of triamcinolone acetonide with or without intravitreal bevacizumab.
  
  
  METHODS
  In 21 eyes, the existence of vitreous incarceration at the pars plana site of intravitreal injection of 0.05 mL of drug was studied by UBM (50 MHz probe of the VUmax, Sonomed, NY), the day after surgery, by 1 technician. The reason for injection was diabetic retinopathy in 12 (57.1%) eyes; age-related macular degeneration in 6 (28.6%) eyes; branch retinal vein occlusion in 2 (9.5%) eyes; and choroiditis in 1 eye (4.8%). In 1 eye, only triamcinolone acetonide was injected, and in the other eyes, bevacizumab mixed with triamcinolone acetonide was injected.
  
  
  RESULTS
  We studied 21 eyes in 13 patients. Of the subjects, 61.5% were male. The mean age of the patients was 62.2 years. On the day after intravitreal injection of the drug, vitreous incarceration into the pars plana site was detected by UBM in 42.9% of the eyes.
  
  
  CONCLUSIONS
  Vitreous incarceration exists after intravitreal injection of drug, but its clinical importance is still unknown. Further long-term prospective studies are recommended.
authors.affiliation: Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran. kamran_jalali@hotmail.com
authors.forename: Kamran
authors.initials: K
authors.lastname: Hodjatjalali
authors.forename: Mohammad
authors.initials: M
authors.lastname: Riazi
authors.forename: Hooshang
authors.initials: H
authors.lastname: Faghihi
authors.forename: Azita
authors.initials: A
authors.lastname: Khorami
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D004359:Drug Therapy, Combination; D005128:Eye Diseases / Q000000981:diagnostic imaging* / Q000209:etiology; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects*; D008297:Male; D033401:Microscopy, Acoustic; D008875:Middle Aged; D012164:Retinal Diseases / Q000188:drug therapy*; D012599:Sclerostomy; D014222:Triamcinolone Acetonide / Q000008:administration & dosage; D014822:Vitreous Body / Q000000981:diagnostic imaging* / Q000473:pathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide